| 项目 | 投资金额（万元） | | --- | --- | | 技源集团营养健康原料生产基地建设项目 | 20628.68 | | 补充流动资金项目 | 15000.00 | | 启东技源营养健康食品生产线扩建项目 | 14730.50 | | 启东技源技术创新中心项目 | 9913.75 | 主要财务指标 | 财务指标/时间 | 2024年 | 2023年 | 2022年 | | --- | --- | --- | --- | | 总资产（亿元） | 11.86 | 10.19 | 9.24 | | 净资产（亿元） | 9.37 | 7.63 | 6.00 | | 营业收入（亿元） | 10.02 | 8.92 | 9.47 | | 净利润（亿元） | 1.74 | 1.60 | 1.42 | | 资本公积（亿元） | 0.8473 | 0.8473 | 0.8473 | | 未分配利润（亿元） | 4.7793 | 3.1239 | 1.6128 | | 基本每股收益（元） | 0.50 | 0.46 | 0.41 | | 每股经营现金流（元） | 0.64 | 0.48 | 0.53 | | 净资产 ...

【隔夜行情】 •周五（2025年7月11日），A股三大指数集体收涨，截至收盘，上证指数涨0.01%，深证成指涨0.61%， 创业板指涨0.8%；北证50涨0.9%。沪深两市成交额约17121.33亿元，较前一个交易日放量约2179.63亿 元。 •周五（2025年7月11日），港股震荡走高，恒指及国指盘中均涨超1%，恒科指一度涨超2%，截止收 盘，恒生指数涨0.46%或111.2点，报24139.57点，全日成交额为3239.5亿港元；恒生国企指数涨0.22%， 报8687.56点；恒生科技指数涨0.61%，报5248.48点。全周来看，恒指累涨0.93%，国指累涨0.91%，恒 科指累涨0.62%。 •周五（当地时间2025年7月11日），美股三大指数收盘集体收跌，道指跌0.63%，纳指跌0.22%，标普 500指数跌0.33%。道指上周累跌1.02%，标普累跌0.31%，纳指累跌0.08%。 【今日新股】 今日2只新股申购，无新股上市。 新股申购： 山大电力，创业板证券代码301609，发行价格14.66元/股，发行市盈率19.57倍；公司是一家致力于电力 系统相关智能产品技术研发与产业化的国家级高新技术 ...

本周（7月14日—7月18日），A股市场将有两只新股开启申购，分别为沪市主板的技源集团和创业板的山大电力，两股均将于本周一申购。 公司专注于全球膳食营养补充行业二十余年，积极布局从营养素分子筛选及评估、功效研究、功能声称及专利申请、市场准入与推广、原料生产到成品制剂加工的 全产业链。公司是全球HMB营养素最主要的开拓者和市场推动者，主导和推动了HMB营养素在多个国家地区的市场准入。公司myHMB®品牌原料已在全球拥有多 项核心专利及丰富的临床数据积累，并入选无锡市重点培育和发展的国际知名品牌名单。公司借助自主开发的氨糖原料精细加工及定制化处理的关键技术，为全球 品牌客户提供高可靠性、高生产效率的定制化原料产品方案，公司GlucosaGreen®品牌原料已逐步成长为全球知名、市场认可度较高的氨糖品牌。 公司现已发展成为全球HMB原料最大供应商和高品质氨糖、制剂等产品核心供应商。公司注册于江苏江阴，管理总部位于上海，在中国和美国均设有研发中心，在 中国香港设立了海外业务中心，并在美国、澳大利亚、英国、日本、挪威等地设立了区域销售总部，同时在江阴、徐州、南通、泰安、澳大利亚布里斯班等地进行 生产布局，已建立起全球化 ...

沪市主板新股技源集团(603262)7月10日晚间披露发行公告，宣布将于今日开启网上申购，申购简称 为"技源申购"，申购代码为732262。 本次公开发行股票数量为5001万股，发行后公司总股本约为4亿股，发行价格确定为10.88元/股。此次 发行采用向参与战略配售的投资者定向配售、网下向符合条件的网下投资者询价配售，以及网上向持有 上海市场非限售A股股份和非限售存托凭证市值的社会公众投资者定价发行相结合的方式进行，中签号 公布日为7月16日。 近年来，受益于膳食营养补充行业的快速发展及下游客户需求的不断提升，公司营业收入及利润规模整 体呈现稳步增长趋势。2022年至2024年，技源集团实现营收9.47亿元、8.92亿元和10.02亿元，净利润为 1.42亿元、1.6亿元和1.74亿元。 技源集团是一家专业从事膳食营养补充产品研发创新及产业化的国际化企业集团。公司专注于全球膳食 营养补充行业二十余年，已建立全球化的研发、生产、销售和服务网络，产品覆盖中国及亚洲、美国、 欧洲、澳大利亚、南美等主要市场。目前，公司已成为全球HMB原料最大供应商和高品质氨糖、制剂 等产品核心供应商，与行业领先客户建立起长期稳定的合 ...

技源集团产品覆盖中国及亚洲、美国、欧洲、澳大利亚、南美等主要市场，并与雅培集团、 Blackmores、Nutramax、PharmaCare等国内外众多膳食营养补充品牌企业建立起长期稳定的合作关系。 业绩方面，2023年至2025年一季度，技源集团实现营收8.92亿元、10.02亿元和2.65亿元，净利润为1.6亿 元、1.74亿元和0.43亿元。 据目前安排，若无变化本周（7月14日到18日）共有2只新股申购，其中上证主板1只，创业板1只。 7月14日启动申购的上证主板新股技源集团（603262），通过垂直整合产业链，覆盖原料生产至成品制 剂加工的全过程，成为国内少数实现营养原料前端至制剂后端垂直整合的企业。其核心产品HMB在全 球市场占据主导地位，2024年全球市占率达53.34%，myHMB品牌更是获得美国药典(USP)认证，成为 同类产品中唯一获此认证的品牌。 本周2股打新 截至发稿，本周网上发行2只新股披露发行价。上证主板新股技源集团发行价为10.88元，发行市盈率 25.95倍，行业最近一个月平均动态市盈率15.28倍。创业板新股山大电力（301609）发行价为14.66元， 发行市盈率19.5 ...

智通财经APP获悉，7月14日，技源集团(603262.SH)开启申购，发行价格为10.88元/股，申购上限为1.2万股，市盈率25.51 倍，行业市盈率27.69，属于上交所主板，东方证券为保荐人。 近年来，凭借先进的研发体系和专利优势、较高的行业地位和品牌认可度，技源集团先后与Formulife(膳食营养)、赛诺菲(膳 食营养)、RoyalCanin(动物营养)、Lintbells(宠物保健)、雀巢公司(食品饮料)、强生公司(膳食营养)、杜邦营养与生物科技集 团(膳食营养)、蒙牛(乳制品)等全球众多知名企业建立合作并陆续实现批量供货，拓宽了公司核心原料及制剂产品的应用领 域和市场空间，为未来业绩的持续增长奠定产品基础和客户基础。 财务方面，于2022年、2023年、2024年，技源集团实现营业收入分别约为9.47亿元、8.92亿元、10.02亿元人民币；同期净利 润分别约为1.44亿元、1.61亿元、1.75亿元人民币。 | 项目 | 2024.12.31 | 2023.12.31 | 2022.12.31 | | --- | --- | --- | --- | | | /2024 年 | /2023 年 ...

Group 1: Technological Innovations and Market Position - Technological Group is the largest global supplier of HMB raw materials, focusing on dietary nutritional supplements and innovative product development [2][3] - The company has established long-term partnerships with renowned brands such as Abbott, Blackmores, and Nutramax, contributing to over 90% of its revenue from overseas markets [7][10] Group 2: Financial Performance and Projections - Technological Group's revenue for 2022, 2023, and 2024 is projected to be 947 million, 892 million, and 1 billion yuan respectively, with net profits of 142 million, 160 million, and 174 million yuan [7][11] - The company anticipates a revenue increase of 15.03% to 27.36% in the first half of 2025, with net profits expected to grow by 8.56% to 19.20% [11][12] Group 3: Business Model and Client Base - Technological Group's business model is centered around the research and development of dietary supplements, with a significant focus on HMB, which aids in muscle synthesis and fatigue reduction [4][10] - The company’s client base includes major players in the dietary supplement industry, ensuring a stable revenue stream [7][10] Group 4: Market Overview and Competitive Landscape - The market for dietary supplements is growing, driven by increasing health awareness and demand for nutritional products, positioning Technological Group favorably within the industry [2][4] Group 5: Company Overview and Offerings - Shanda Electric is a high-tech enterprise focused on the research and development of intelligent products related to power systems, with major products including fault recording and monitoring devices [13][15] - The company derives approximately 80% of its revenue from electric grid enterprises, with 70% coming specifically from the State Grid [15][16] Group 6: Financial Performance and Future Outlook - Shanda Electric's revenue for 2022, 2023, and 2024 is projected to be 478 million, 549 million, and 658 million yuan respectively, with net profits of 76.99 million, 103 million, and 127 million yuan [17][18] - The company expects a revenue increase of 13.55% to 21.66% in the first half of 2025, with net profits projected to grow by 14.87% to 24.65% [19][20]

【导读】下周一两只新股可申购，山大电力收入有赖于国家电网 中国基金报记者 闻言 A股打新投资者注意啦！ 根据目前发行安排，7月14日有两只新股可申购，分别是上交所主板新股技源集团、深交所创业板新股山大电力。 技源集团系全球HMB原料最大供应商 技源集团的申购代码是732262，发行价为10.88元/股，发行市盈率为25.51倍，参考行业市盈率为27.69倍。 技源集团此次总发行数量为5001万股，网上发行数量为1200万股。投资者参与网上申购技源集团，申购数量上限为1.2万股，顶格申购需 配沪市市值为12万元。 技源集团从事膳食营养补充产品的研发创新与产业化发展，已发展成为全球HMB原料的最大供应商，以及高品质氨糖、制剂等产品的核心 供应商，近年来境外收入占 其 总收入的比重均超90%。 | 地区 | 2024 年 | | 2023 年 | | 2022 年 | | | --- | --- | --- | --- | --- | --- | --- | | | 金额 | 比例 | 金额 | 比例 | 金额 | 比例 | | 境外 | 93,848.10 | 93.93% | 84,754.69 | 95.25 ...

Core Viewpoint - The conference on Traditional Chinese Medicine (TCM) nutrition management for diabetes highlighted innovative strategies integrating TCM and modern nutrition to provide personalized health management for diabetes patients [1][2]. Group 1: Conference Overview - The conference was held on June 21 in Hangzhou, organized by Xiamen Tanglaibang Medical Nutrition Research Center, featuring experts from TCM, nutrition, and endocrinology [1]. - The event included keynote speeches, case sharing, and interactive discussions, showcasing the unique value of integrated TCM nutrition interventions in diabetes prevention and treatment [1]. Group 2: Key Presentations - Professor Wang Hongcai emphasized that TCM treatment for diabetes focuses not only on lowering blood sugar but also on restoring overall bodily functions [2]. - Professor Zou Aibiao discussed the relationship between gut health and diabetes, highlighting that gut microbiome imbalance is closely related to insulin resistance and chronic inflammation, and that dietary interventions can improve glucose metabolism [2]. - Professor Hu Renming presented the "Four Diseases Co-Treatment" strategy, addressing the common mechanisms of diabetes, obesity, fatty liver, and atherosclerosis through the lens of chronic low-grade inflammation [2]. Group 3: Future Directions - The founder of Xiamen Tanglaibang Medical Nutrition Research Center stated the intention to further develop TCM nutrition intervention methods and promote standardized, scientific diabetes management solutions to benefit more patients with a "Chinese-style blood sugar control" model [3].

Core Viewpoint - The strategic placement of shares in the initial public offering (IPO) of Jiyuan Group Co., Ltd. has been approved, with a total of 5,001,000 shares to be publicly issued, representing 12.50% of the total post-issue share capital [1][3]. Group 1: Strategic Placement Overview - The initial strategic placement amount is set at 1,000,200 shares, accounting for 20.00% of the total issuance [3][5]. - The strategic placement will involve four investors, with the participation of senior management and core employees through a special asset management plan [5][9]. - The total share capital of the company post-issue will be 40,001,000 shares [3]. Group 2: Investor Participation - The strategic placement is limited to investors who meet specific criteria outlined in the Implementation Rules, ensuring compliance with legal requirements [2][16]. - The senior management and core employees' asset management plan will not exceed 500,100 shares, which is 10% of the total issuance [5][9]. - Other participating investors are allowed to commit up to 60,000,000 yuan [3][5]. Group 3: Compliance and Verification - The underwriter has verified that all participating investors have provided valid documentation and guarantees regarding their qualifications [2][15]. - The strategic placement agreement stipulates that investors will not participate in the preliminary inquiry and will commit to the final issuance price [8][16]. - The lock-up period for shares acquired through the strategic placement is set at 12 months from the date of the IPO [16][28]. Group 4: Investor Profiles - Ningbo Tongshang Hui Gong Industrial Investment Fund, a large enterprise with strategic ties to the issuer, is among the investors [4][23]. - Meinian Health Industry Holding Co., Ltd., a leading health examination company, is also participating, leveraging its extensive data for collaboration [24][28]. - Hangzhou Minsheng Health Pharmaceutical Co., Ltd. is included as well, focusing on health-related products and services [29][30].